1-3 of 3
Elena Ivanova
Close
Sort by
Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL) Treated with Zanubrutinib+ Obinutuzumab Versus Obinutuzumab Monotherapy: The Rosewood Trial

Judith Trotman, Pier Luigi Zinzani, Yuqin Song, Richard Delarue, Gisoo Barnes, Pil Kim, Elena Ivanova, Boxiong Tang, Jiří Mayer, Ana C. De Oliveira, Sarit Assouline, Christopher R. Flowers
Journal: Blood
Blood (2023) 142 (Supplement 1): 1674.
https://doi.org/10.1182/blood-2023-181195
Published: 2023
Journal Articles

Randomized Phase 2 Zanubrutinib (BGB-3111) + Obinutuzumab Vs Obinutuzumab Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL)

Nathan H. Fowler, MD, Judith Trotman, MBChB, FRACP, FRCPA, Rebecca Auer, MRCP, FRPath, PhD, Christopher R. Flowers, MD MS, William F. Reed, MD, Elena Ivanova, PhD, Jane Huang, MD, Pier Luigi Zinzani, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5252.
https://doi.org/10.1182/blood-2019-122628
Published: 2019
Journal Articles

A Dose-Escalation (DE) Study with Expansion Evaluating Safety, Pharmacokinetics and Efficacy of the Novel, Balanced PI3K/mTOR Inhibitor PQR309 in Patients with Relapsed or Refractory Lymphoma

Graham P. Collins, MD PhD, Rakesh Popat, Anastasios Stathis, Fatime Krasniqi, MD PhD, Toby A. Eyre, MD, Chin Hin Ng, MD, Dima El-Sharkawi, MD, Christian Schmidt, MD, Andreas Wicki, MDPhD, Elena Ivanova, PhD, Debora Schmitz, PhD, Sasa Dimitrijevic, PhD, Martin H. Dreyling, MD PhD
Journal: Blood
Blood (2016) 128 (22): 5893.
https://doi.org/10.1182/blood.V128.22.5893.5893
Published: 2016